Article Correctness Is Author's Responsibility: New study supports the safety of varenicline

(Society for the Study of Addiction) A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT). These findings confirm those of earlier clinical trials, providing further evidence of the safety of varenicline as an aid to stop smoking.